Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMZMG96)

Drug Name	ALLN-346 DMZMG96
Drug Type	Enzyme replacement

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Gout	DISHC0U7	FA25	Phase 2	[1]
Chronic kidney disease	DISW82R7	GB61	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04987242) An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04987294) A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease. U.S.National Institutes of Health.